Xiangjun Liu

Dr. Xiangjun Liu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XCXing-yu Cao
Xing-yu Cao
HZHai-Fei Zhou
Hai-Fei Zhou
XLXiangjun Liu
Xiangjun Liu
XLXiao-Bo Li
Xiao-Bo Li
Introduction: The human leukocyte antigen (HLA) evolutionary divergence (HED) reflects immunopeptidome diversity and has been shown to predict the response of tumors to immunotherapy. Its impact on allogeneic hematopoietic stem cell transplantation (HSCT) is controversial in different studies.Methods: In this study, we retrospectively analyzed the clinical impact of class I and II HED in 225 acute lymphoblastic leukemia patients undergoing HSCT from related haploidentical donors. The HED for recipient, donor, and donor-recipient pair was calculated based on Grantham distance, which accounts for variations in the composition, polarity, and volume of each amino acid within the peptide-binding groove of two HLA alleles. The median value of HED scores was used as a cut-off to stratify patients with high or low HED.Results: The class I HED for recipient (R_HEDclass I) showed the strongest association with cumulative incidence of relapse (12.2 vs. 25.0%, P = 0.00814) but not with acute graft-versus-host disease. The patients with high class II HED for donor-recipient (D/R_HEDclass II) showed a significantly higher cumulative incidence of severe aGVHD than those with low D/R_HEDclass II (24.0% vs. 6.1%, P = 0.0027). Multivariate analysis indicated that a high D/R_HEDclass II was an independent risk factor for the development of severe aGVHD (P = 0.007), and a high R_HEDclass I had a more than two-fold reduced risk of relapse (P = 0.028). However, there was no discernible difference in overall survival (OS) or disease-free survival (DFS) for patients with high or low HED, which was inconsistent with the previous investigation.Discussion: While the observation are limited by the presented single center retrospective cohort, the results show that HED has poor prognostic value in OS or DFS, as well as the associations with relapse and aGVHD. In haploidentical setting, class II HED for donor-recipient pair (D/R_HEDclass II) is an independent and novel risk factor for finding the best haploidentical donor, which could potentially influence clinical practice if verified in larger cohorts.

21 January 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
WNWeijian Nie
Weijian Nie
YWYan Wang
Yan Wang
QFQian Fu
Qian Fu
CWChenglin Wu
Chenglin Wu
RDRonghai Deng
Ronghai Deng
CWChangxi Wang
Changxi Wang
Background: This study aimed to assess the diagnostic accuracy of combining donor-derived cell-free DNA (dd-cfDNA) fraction and absolute quantification in detecting kidney allograft rejection. Methods: A prospective study was conducted from December 2019 to April 2021 at the First Affiliated Hospital of Sun Yat-sen University. Kidney transplant recipients who underwent biopsy, including cases of T-cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR), and borderline rejection, were included. dd-cfDNA fraction and absolute concentrations were measured, and diagnostic efficacy was evaluated using receiver operating characteristic (ROC) analysis. The double-positive and double-negative methods were applied to assess performance. Results: A total of 50 kidney transplant recipients were included. The dd-cfDNA fraction cutoff of 1.08% achieved 93.33% sensitivity and 91.43% specificity (AUC = 0.95), with an NPV of 96.97% and a PPV of 82.35%. The absolute dd-cfDNA threshold of 32 cp/mL yielded 80.00% sensitivity and 71.43% specificity (AUC = 0.78), with an NPV of 89.29% and a PPV of 54.55%. The double-positive method provided superior accuracy, with a PPV of 91.67% and an NPV of 89.47%, demonstrating 73.33% sensitivity and 97.14% specificity. The double-negative method achieved 100% NPV and 100% sensitivity. Conclusions: Combining dd-cfDNA fraction and absolute quantification improves diagnostic accuracy for kidney transplant rejection, especially ABMR. The double-positive and double-negative approaches show high predictive value, offering potential clinical value for monitoring kidney transplant recipients.

26 August 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XTXiang-Feng Tang
Xiang-Feng Tang
YLYan-Hui Luo
Yan-Hui Luo
YSYing-Jian Si
Ying-Jian Si
MQMao-Quan Qin
Mao-Quan Qin
WLWei Lu
Wei Lu
XLXiangjun Liu
Xiangjun Liu
Introduction: Relapse continues to be a major factor contributing to therapeutic failure in haploidentical hematopoietic stem cell transplantation (HSCT). The role of natural killer (NK) cell alloreactivity mediated by killer immunoglobulin-like receptors (KIRs) is considered important in postoperative immune reconstitution and in mitigating relapse. However, its clinical implications remain incompletely defined, and its impact on allogeneic HSCT is controversial across studies.Methods: In the present investigation, we assessed the effect of predicted NK cell alloreactivity through KIR–ligand interactions on relapse and survival outcomes in a pediatric cohort. This retrospective study included pediatric patients who underwent their first haploidentical HSCT following the Beijing protocol between 2013 and 2023. Both low- and high-resolution typing methods were employed for all donor and patient samples. The presence of NK cell alloreactivity was determined using predictive models incorporating the HLA class I molecules of both donors and recipients. NK cell alloreactivity was classified as ALLO or Non-ALLO based on the presence or absence of predicted alloreactivity, and its effects on relapse and overall survival were evaluated through individual and combinatorial interactions.Results: Multivariate analysis demonstrated that, among patients lacking A3/A11, those who received grafts from donors with both KIR3DL2+ and A3/A11+ had an 86% lower risk of relapse (adjusted hazard ratio 0.136; p = 0.0489). Both Synthesis-iKIR and combined Synthesis-iKIR/KIR2DS1 showed significant independent effects on overall survival, with clinically adjusted hazard ratios of 0.305 and 0.316 (p < 0.005), respectively. The disease state at transplantation was an independent clinical factor influencing prognosis. Other additive models failed to effectively predict clinical outcomes in pediatric recipients.Discussion: These results indicate that pediatric patients exhibiting NK cell alloreactivity, as predicted by the KIR3DL2–A3/A11 combination, had a significantly lower cumulative incidence of relapse. Furthermore, alloreactivity predicted by Synthesis-iKIR was significantly associated with improved overall survival. These findings have not been previously validated in pediatric studies and may have clinical relevance for haploidentical transplantation population, pending confirmation in larger cohorts.

9 June 2026 in Kidney International Reports
Verified
Journal Article
Open access
WZWeitao Zhang
Weitao Zhang
JHJunbo He
Junbo He
XYXiaotian Yan
Xiaotian Yan
DZDong Zhu
Dong Zhu
TZTongyu Zhu
Tongyu Zhu
JWJina Wang
Jina Wang

25 August 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XTXiang-Feng Tang
Xiang-Feng Tang
HZHai-Fei Zhou
Hai-Fei Zhou
WZWei-Jie Zhang
Wei-Jie Zhang
YLYan-Hui Luo
Yan-Hui Luo
XWXiao-Qi Wang
Xiao-Qi Wang
JWJingbo Wang
Jingbo Wang
Introduction: Natural killer cell alloreactivity contributes to the graft-versus-leukemia (GVL) effect of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). However, its importance remains controversial across studies. Methods: In this retrospective analysis, we studied NK cell alloreactivity and its association with clinical outcomes using the education model in patients with hematologic malignancies undergoing transplantation. Patients were stratified by the presence or absence of alloreactivity assessment, which was defined by the coexistence (in the donor) of four germline-encoded inhibitory killer cell immunoglobulin-like receptors (iKIRs) and their corresponding self-human leukocyte antigen (HLA)-I ligands. Results: In a cohort of 1,209 patients,793 individuals (65.6%) had no loss of iKIR ligands, while 416 cases showed alloreactivity characterized by the absence of at least one ligand. Among the missing single ligand, the absence of HLA-A3/A11 epitope was the most prevalent (28.4%), followed by Bw4 (25.2%), C2 (23.6%), and C1 (10.6%). Only patients with KIR3DL2-A3/A11-mediated alloreactivity exhibited a substantially reduced 3-year cumulative incidence of relapse (CIR) compared to those without this predicted alloreactivity (16.2%; 95% confidence interval [CI], 10.1-23.5%; and 30.1%; 95% CI, 27.1-33.3%; P = 0.0006). Multivariate analysis confirmed A3/A11 deficiency as an independent protective factor against relapse (adjusted hazard ratio 0.487; 95% CI, 0.300-0.790; P = 0.0035). Moreover, alternative predictive models failed to reliably forecast relapse risk. Discussion: Our result suggest that NK cell alloreactivity driven by the absence of HLA-A3/A11 may enhance NK cell-mediated surveillance against leukemia cells; therefore, incorporating KIR3DL2-A3/A11 compatibility assessment can refine donor selection strategies aimed at reducing relapse incidence in patients undergoing haplo-HSCT.

23 July 2026 in Organ Medicine
Verified
Journal Article
Open access
RDRonghai Deng
Ronghai Deng
WCWengen Chen
Wengen Chen
XCXinhua Chang
Xinhua Chang
ZCZehuan Chen
Zehuan Chen
QYQianyu Ye
Qianyu Ye
XLXiangjun Liu
Xiangjun Liu
Background: The recurrence of immunoglobulin A nephropathy (IgAN) after kidney transplantation (KT) is common and compromises long‐term graft survival; however, the early identification of patients at high risk of recurrence remains a clinical challenge. This study evaluated the roles of serum galactose‐deficient IgA1 (Gd‐IgA1), proliferation‐inducing ligand (APRIL), and B‐cell activating factor (BAFF) in predicting post‐transplant IgAN recurrence. Methods: This retrospective case–control study included patients with primary IgAN who underwent KT at the First Affiliated Hospital, Sun Yat‐sen University, from September 2014 to June 2023. Patients were divided into two groups: post‐transplantation IgAN recurrence ( n = 19) and non‐recurrence ( n = 25). Serum levels of Gd‐IgA1, APRIL, and BAFF were measured pre‐transplantation and at 3, 6, 12, 24, and 36 months post‐transplantation. Results: Recipients of kidneys from living donors had a significantly higher risk of IgAN recurrence compared with deceased‐donor recipients (odds ratio = 30.6, p = 0.001). Serum Gd‐IgA1 levels showed good discriminative ability for recurrence at 3 months (area under the curve: 0.85, 95% confidence interval: 0.72–0.99) and 6 months (area under the curve: 0.89, 95% confidence interval: 0.76–1.00) after transplantation. Elevated Gd‐IgA1 levels at 3 and 6 months were significantly associated with recurrence in univariate analyses, and remained the only independent predictor in multivariate Cox models. BAFF levels were significantly lower in the recurrence group at 12 months, while APRIL levels did not differ between the groups at any time point. Conclusions: Serum Gd‐IgA1 levels could effectively predict IgAN recurrence risk in patients post‐KT.